Abstract
The aim was to determine whether promoter methylation of BRCA1, MGMT, MLH1, RASSF1A, and p16 genes could predict response to platinum-based chemotherapy. Thirty-five subjects with epithelial ovarian cancer (EOC) treated by platinum-based chemotherapy were recruited. Methylation-specific polymerase chain reaction was carried out and the methylation index (MI) was also derived. Response to platinum-based chemotherapy was documented clinically, radiologically, and by serial CA125 levels. Methylated BRCA1 (p = .037) and a higher MI (p = .045) were associated with primary chemosensitivity. A better outcome was predicted by a higher MI (p = .032). In EOC, BRCA1 gene promoter methylation is useful in the prediction of response to chemotherapy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adaptor Proteins, Signal Transducing / genetics
-
Adult
-
Antineoplastic Agents / therapeutic use*
-
BRCA1 Protein / genetics*
-
CA-125 Antigen / blood
-
Cisplatin / therapeutic use*
-
CpG Islands*
-
Cyclin-Dependent Kinase Inhibitor p16 / genetics
-
DNA Methylation*
-
DNA Modification Methylases / genetics
-
DNA Repair Enzymes / genetics
-
Disease-Free Survival
-
Female
-
Humans
-
Middle Aged
-
MutL Protein Homolog 1
-
Nuclear Proteins / genetics
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / genetics
-
Ovarian Neoplasms / immunology
-
Pilot Projects
-
Predictive Value of Tests
-
Promoter Regions, Genetic*
-
Time Factors
-
Treatment Outcome
-
Tumor Suppressor Proteins / genetics
Substances
-
Adaptor Proteins, Signal Transducing
-
Antineoplastic Agents
-
BRCA1 Protein
-
BRCA1 protein, human
-
CA-125 Antigen
-
Cyclin-Dependent Kinase Inhibitor p16
-
MLH1 protein, human
-
Nuclear Proteins
-
RASSF1 protein, human
-
Tumor Suppressor Proteins
-
DNA Modification Methylases
-
MGMT protein, human
-
MutL Protein Homolog 1
-
DNA Repair Enzymes
-
Cisplatin